entertainment -WSS

entertainment

author：entertainment 2025-09-03 05:33:33 - browse：674

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Device maker Teleflex to acquire urology company for $600M

focus

WSS

What it's like to live with paralysis for one psychologist

Dems pitch expanding Medicare power to negotiate drug prices

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

What to watch for from Zogenix and Amicus clinical trials

What to watch for from Zogenix and Amicus clinical trials

The battle over 'scope creep' and who gets to be called 'doctor'

focus

entertainment

explore

23andMe had bad news about my health. I wish a person had delivered it

Biden warns of ‘dark winter’ during final presidental debate

United colonoscopy coverage change 'may cost lives,' doctors say

Will the FTC rein in IQVIA's health data empire?

Apple is now the first public company to be valued at $3 trillion

Do more moles mean more problems? Not so, says new study

Peter Hotez and the public health issue of online harassment

New Alzheimer's drugs heat up race for early detection blood tests

In age of alternative facts, a scholarly course on calling out crap

Search called off for baby washed away in Pennsylvania flash flood

focus

AI used to predict Covid

STAT Report: Patient voices and perspectives

Childbirth

New lawsuit accuses health insurer Cigna of denying claims in bulk

Lab trade group sues FDA to halt regulation of lab

Dark money group runs ads on China biotech bill

entertainment

focus

focus

focus